Last reviewed · How we verify

fennel

University of Karachi · FDA-approved active Biologic Quality 2/100

Fennel, marketed by the University of Karachi, is a drug with a key composition patent expiring in 2028. The primary strength of Fennel lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the potential increase in competition post-2028, when the key patent expires.

At a glance

Generic namefennel
Also known asFoeniculum vulgare
SponsorUniversity of Karachi
ModalityBiologic
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results